rivaroxaban - Articles and news items

Janssen Pharmaceuticals Logo

FDA Advisory Committee recommends against approval of the use of oral anticoagulant XARELTO® to reduce the risk of thrombotic cardiovascular events in patients with Acute Coronary Syndrome

Industry news / 16 January 2014 / Johnson & Johnson

Janssen is seeking approval of rivaroxaban at a proposed dose of 2.5 mg twice daily (BID) for a 90 day treatment duration…

Boehringer Ingelheim logo

Cost effectiveness and clinical efficacy of Pradaxa® (dabigatran etexilate) versus rivaroxaban analysed

Industry news, News / 24 August 2012 / Boehringer Ingelheim

Indirect comparison based on the RE-LY® trial and the Rocket AF trial suggests advantages of Pradaxa® in stroke prevention in patients with atrial fibrillation…

Bayer logo

Bayer’s Xarelto® approved in the EU for the prevention of stroke in patients

Industry news / 20 December 2011 / Bayer HealthCare

The only new oral anticoagulant approved in three indications across all 27 EU member states…

 

The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...
+